Boston Partners’s Pacira BioSciences PCRX Stock Holding History

Boston Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-29,977	Closed	-$858K	–	748
2024 Q2	$858K	Buy	29,977 +8,907	+42%	+$254K	﹤0.01%	609
2024 Q1	$616K	Sell	21,070 -36,748	-64%	-$1.13M	﹤0.01%	660
2023 Q4	$1.95M	Sell	57,818 -50,691	-47%	-$1.48M	﹤0.01%	502
2023 Q3	$3.33M	Buy	108,509 +55,679	+105%	+$2.01M	﹤0.01%	441
2023 Q2	$2.12M	Sell	52,830 -24,880	-32%	-$1.03M	﹤0.01%	474
2023 Q1	$3.17M	Buy	77,710 +156	+0.2%	+$6.21K	﹤0.01%	429
2022 Q4	$2.99M	Sell	77,554 -23,035	-23%	-$1.12M	﹤0.01%	419
2022 Q3	$5.35M	Buy	100,589 +56,282	+127%	+$3.13M	0.01%	388
2022 Q2	$2.58M	Buy	44,307 +362	+0.8%	+$23.7K	﹤0.01%	419
2022 Q1	$3.35M	Buy	43,945 +32,351	+279%	+$2.16M	﹤0.01%	419
2021 Q4	$698K	Buy	+11,594	New	+$639K	﹤0.01%	577

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Boston Partners's PCRX Position: Q3 2024 in Review

Boston Partners sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 29,977 shares — an estimated $858K sold.

Boston Partners first reported a position in PCRX in Q4 2021 and held it in 11 quarters. The position peaked at $5.35M in Q3 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Boston Partners reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Boston Partners sold 29,977 Pacira BioSciences shares in Q3 2024, an estimated $858K.
Boston Partners first reported a position in Pacira BioSciences in Q4 2021 and held it in 11 quarters.
Boston Partners's Pacira BioSciences position peaked at $5.35M in Q3 2022.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Boston Partners's 13F filing for Q3 2024, filed 12 Nov 2024.